Chemoinformaics analysis of Neoandrographolide
| Molecular Weight | 480.598 | nRot | 7 |
| Heavy Atom Molecular Weight | 440.278 | nRig | 23 |
| Exact Molecular Weight | 480.272 | nRing | 4 |
| Solubility: LogS | -3.25 | nHRing | 2 |
| Solubility: LogP | 2.271 | No. of Aliphatic Rings | 4 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 2 |
| Atoms Count | 74 | No. of Aliphatic Hetero Cycles | 2 |
| No. of Heavy Atom | 34 | No. of Aromatic Carbocycles | 0 |
| nHetero | 8 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 2 |
| No. of Hydrogen atom | 40 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 26 | No. of Saturated Rings | 3 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 8 | No. of Arom Bond | 0 |
| nHA | 8 | APOL | 76.5077 |
| nHD | 4 | BPOL | 46.2043 |
| QED | 0.376 |
| Synth | 4.963 |
| Natural Product Likeliness | 2.476 |
| NR-PPAR-gamma | 0.091 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.001 |
| Pgp-sub | 0.019 |
| HIA | 0.804 |
| CACO-2 | -5.512 |
| MDCK | 0.00000797 |
| BBB | 0.127 |
| PPB | 0.912472 |
| VDSS | 1.204 |
| FU | 0.0695442 |
| CYP1A2-inh | 0.006 |
| CYP1A2-sub | 0.158 |
| CYP2c19-inh | 0.006 |
| CYP2c19-sub | 0.157 |
| CYP2c9-inh | 0.011 |
| CYP2c9-sub | 0.275 |
| CYP2d6-inh | 0.003 |
| CYP2d6-sub | 0.281 |
| CYP3a4-inh | 0.028 |
| CYP3a4-sub | 0.084 |
| CL | 1.859 |
| T12 | 0.172 |
| hERG | 0.007 |
| Ames | 0.087 |
| ROA | 0.567 |
| SkinSen | 0.028 |
| Carcinogencity | 0.067 |
| EI | 0.006 |
| Respiratory | 0.874 |
| NR-Aromatase | 0.688 |
| Antiviral | Yes |
| Prediction | 0.909816 |